News | September 10, 2013

MRI Before Ablation for Atrial Fibrosis Helps Predict Success of Treatment

Late-breaking trials on intervention and device

September 10, 2013 — In patients with atrial fibrillation, delayed enhancement magnetic resonance imaging (DE-MRI) performed before ablative treatment can stage the degree of damaged heart tissue (atrial fibrosis) and help predict whether treatment will be successful or not, according to results of the Delayed Enhancement — MRI determinant of successful Catheter Ablation of Atrial Fibrillation (DECAAF) trial.

"The DECAAF results show that stage of atrial fibrosis prior to ablation is a new, powerful, independent predictor of outcome," said lead investigator Nasir Marrouche, M.D., from the CARMA Center at the University of Utah in Salt Lake City.

"By performing this imaging before ablative treatment we can triage patients according to likelihood of treatment success, and avoid ablative procedures in those patients for whom it is unlikely to work. If a patient has late stage 3 or stage 4 fibrosis their chance of being cured is only 30-35 percent, which is really low, but if they're in an early stage their chance of cure is 60-80 percent," he said.

The DECAAF trial included 260 atrial fibrillation (AF) patients with atrial fibrosis who were undergoing ablation.

The patients, from 15 centers in the United States, Europe and Australia were a mean age of 59 years, and 64.6 percent of them had paroxysmal AF.

High resolution Delayed Enhancement MRI (DE?MRI) was performed up to 30 days before ablation in all patients to determine the presence and extent of atrial fibrosis, while post- ablation DE-MRI was performed at 90-days follow-up in 177 of the subjects, to determine the extent of residual ablation.

At the 90-day follow-up, recurrence of arrhythmia was noted in 88 of the 260 patients (33.8 percent) based on Holter monitors and electrocardiograms.

Multivariate analysis revealed two independent predictors of successful ablation or recurrent symptoms were stage of atrial fibrosis before ablation (P<0.001) as well as residual fibrosis after (P<0.001).

Specifically, patients whose pre-ablation fibrosis was stage 1 (defined as less than 10% damaged atrial tissue) had an 85.8% success rate, those with stage 2 (10% - 20% damage) had a 63.3% success rate, those with stage 3 (20% - 30% damage) had a 55% success rate and those with stage 4 (more than 30% damage) had a 31% success rate.

For every increased percentage of fibrosis before ablation, there was 6.3% increased risk of recurrent symptoms after ablation (hazard ratio [HR] 1.063), said Marrouche.

Similarly, for every percentage of residual fibrosis there was an 8.2 percent increased risk of recurrent symptoms (HR 1.082).

A secondary finding of the study, based on post-ablation imaging, showed that the type of ablation clinicians used also had an impact on success rates. The choice of procedure was not dictated in the study protocol and was left to the discretion of individual treating physicians.

After comparing pre-ablation images of fibrotic tissue, with post-ablation images showing the extent of residual fibrosis, a surprise finding was that pulmonary vein ablation, which is the standard-of-care in atrial fibrillation ablation candidates, is not the best ablative approach, said Marrouche.

"We do ablation around the pulmonary veins because we have assumed for years that the trigger for AF comes from the vein — that's the standard of care," he said. "But what we found in DECAAF is that ablation of the veins did not predict outcome. In fact, the most important predictor of outcome, along with stage of atrial fibrosis, was the degree of ablation of the fibrotic tissue. Rather than targeting the pulmonary veins, procedures which ablated fibrotic tissue produced better outcomes - the more that was targeted, the better the outcome."

For more information: europace.oxfordjournals.org/content/current

DISCLOSURES: Marrouche disclosed that he has received honoraria from: Biotronik, Siemens, Boston Scientific, and Boehringer Ingelheim; he has received consulting fees from: Sanofi and eCardio; he has received research grants from eCardio and estech; he has received equipment from Siemens; he has stock options with MRI-Intervetions; and holds stock in Marreck Inc.

Related Content

New Multi-Center Research Effort to Focus on Early Life Origins of Heart Health
News | Congenital Heart| June 23, 2017
Heart health in children will be the focus of three closely synergistic research projects and an integrated...
Feature | EP Lab| June 22, 2017 | Dave Fornell
Electrophysiology (EP) technology has been advancing rapidly the past few years with new ablation tools to improve ar
Pacemakers and Other Cardiac Devices Can Help Solve Forensic Cases
News | Pacemakers| June 20, 2017
Pacemakers and other cardiac devices can help solve forensic cases, according to a study presented at the European...
BioImage-2 Study to Investigate Atherosclerotic Disease Progression
News | Cardiovascular Ultrasound| June 20, 2017
Mount Sinai Heart and BioImage-2 LLC recently announced the start of the BioImage-2 study investigating the progression...
News | June 12, 2017
June 12, 2017 – Med Alliance announced completion on schedule of patient enrollment in the first-in-man (FIM) study o
LivaNova Announces Positive Data for Perceval Sutureless Valve at AATS 2017
News | Heart Valve Technology| May 31, 2017
LivaNova PLC recently announced the presentation of data from multiple studies demonstrating the safety and...
Head-to-Head Study Validates Consistent Performance of Microcatheter FFR
News | FFR Catheters| May 31, 2017
Acist Medical Systems Inc. announced results from the ACIST-FFR Study demonstrating the consistent and correlative...
FFR-Search Registry Reveals Impact of Post-PCI Fraction Flow Reserve Measurement on Outcomes
News | FFR Catheters| May 30, 2017
Early results from the independent, physician-sponsored FFR-Search Registry revealed an association between post-...
Data was positive from the Watchman Left Atrial Appendage Closure (LAAC) Device from the EWOLUTION registry
News | Atrial Fibrillation| May 30, 2017
May 30, 2017 — Data was positive for safety and efficacy rates of the Watchman Left Atrial Appendage Closure (LAAC) D
Abbott SJM Confirm RX Implantable cardiac monitor gains european CE mark approval
News | May 30, 2017
May 30, 2017 — Abbott recently announced European CE mark and first use of the new Confirm Rx Insertable Cardiac Moni
Overlay Init